Clinical Analysis of 1,068 Cases of Mid-trimester Genetic Amniocentesis.
- Author:
Hyun Hee PARK
;
Seong Cheon YANG
;
Haeng Soo KIM
;
Jeong In YANG
;
Joon Hwan OH
;
Hyun Woong KANG
;
Hyun Joo KIM
;
Yeon Jong JOO
;
Kie Suk OH
- Publication Type:Original Article
- Keywords:
Genetic amniocentesis;
Chromosomal abnormalities
- MeSH:
Age Distribution;
Amniocentesis*;
Amniotic Fluid;
Anti-Bacterial Agents;
Biomarkers;
Chromosome Aberrations;
Female;
Fetal Death;
Gynecology;
Humans;
Incidence;
Obstetrics;
Pregnancy;
Pregnancy Outcome;
Pregnancy Trimester, Second;
Prenatal Diagnosis;
Ultrasonography
- From:Korean Journal of Obstetrics and Gynecology
1999;42(10):2306-2314
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The objective of this study is to analyze 1,068 cases of prenatal genetic amniocentesis and to compare the results with reported studies. METHOD: We analyzed 1,068 cases of midtrimester prenatal genetic amniocenteses from September 1994 to February 1999, and investigated the fetal chromosomal abnormality, obstetric outcomes and complications by the indications of genetic amniocentesis and prophylactic antibiotic use at the Department of Obstetrics and Gynecology, Ajou University School of Medicine. RESULTS: Abnormal maternal serum markers were the most common indication of amniocentesis (57.7%) and the most common age distribution was 25-29 years (39.2%). One case of early amniocentesis (14 gestational weeks) was performed. The overall incidence of chromosomal aberration was 5.2% (56/1,068), of which there were 28 cases (50.0%; 28/56) of numerical aberrations and 28 cases (50.0%; 28/56) of structural aberrations. There were 50 cases (4.7%) of autosomal chromosomal aberrations and 6 cases (0.6%) of sex chromosomal aberrations. The pregnancy outcome was full-term delivery in 86.5%, preterm delivery in 7.6%, termination of pregnancy in 4.0%. There were no cases of serious complications including fetal death except for a case of self-limited amniotic fluid leakage(high leakage) in which the pregnancy was maintained. There were no significant differences between prophylactic antibiotics user group and non-user group in obstetric complications and outcomes. CONCLUSION: We could confirm that the trend in the indication of genetic amniocentesis had changed from advanced maternal age(35 year-old) toward abnormal maternal serum marker(triple test), and we recognized the importance of genetic amniocentesis according to the various antenatal screening tests of maternal serum marker, antenatal ultrasound, past history of fetal anomaly or family history of fetal chromosomal anomaly in the younger age groups(< 35 year-old) that are involved in more than half of the chromosomal anomaly. Further study will be needed to elucidate the efficacy of using prophylactic antibiotics in amniocentesis.
